Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Acoramidis shows strong benefits in treating ATTR-CM, reducing heart failure and hospitalizations.
BBIO
$82.33
-$1.77 -2.10%

Acoramidis shows strong benefits in treating ATTR-CM, reducing heart failure and hospitalizations.

Company Fundamentals
11 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduces serum transthyretin variability and outpatient worsening heart failure, showing early and sustained benefits. The Phase 3 ATTRibute-CM study demonstrated a 34% reduction in cardiovascular hospitalizations compared to tafamidis, with a favorable mortality trend and comparable safety. These results highlight acoramidis as a fast-acting, effective treatment option for ATTR-CM, approved in multiple regions, with ongoing data presentations planned.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App